Page 18 - Read Online

Monge Bonilla et al. Hepatoma Res 2020;6:68 I http://dx.doi.org/10.20517/2394-5079.2020.58 Page 13 of 14

hepatitis C virus-specific CD4+ T-cell proliferation in patients with hepatitis C virus infection. Immunology 2007;121:283-92.
62. Ulsenheimer A, Gerlach JT, Gruener NH, Jung MC, Schirren CA, et al. Detection of functionally altered hepatitis C virus-specific CD4 T
cells in acute and chronic hepatitis C. Hepatology 2003;37:1189-98.
63. Cancer Genome Atlas Research Network. Electronic address: wheeler@bcm.edu. Cancer Genome Atlas Research Network.
Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 2017;169:1327-41.e23.
64. Zheng C, Zheng L, Yoo JK, Guo H, Zhang Y, et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing.
Cell 2017;169:1342-56.e16.
65. Kim HD, Song GW, Park S, Jung MK, Kim MH, et al. Association between expression level of PD1 by tumor-infiltrating CD8+ T cells
and features of hepatocellular carcinoma. Gastroenterology 2018;155:1936-50.e17.
66. Lim CJ, Lee YH, Pan L, Lai L, Chua C, et al. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-
related hepatocellular carcinoma. Gut 2019;68:916-27.
67. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Krüger C, et al. A new population of myeloid-derived suppressor cells in hepatocellular
carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008;135:234-43.
68. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer.
Cancer Res 2006;66:11238-46.
69. Ugel S, De Sanctis F, Mandruzzato S, Bronte V. Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-
associated macrophages. J Clin Invest 2015;125:3365-76.
70. Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-
bound TGF-beta 1. J Immunol 2009;182:240-9.
71. Zhang HH, Mei MH, Fei R, Liu F, Wang JH, et al. Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of
hepatocellular carcinoma by suppressing the anti-tumour immune responses. J Viral Hepat 2010;17 Suppl 1:34-43.
72. Han Y, Chen Z, Yang Y, Jiang Z, Gu Y, et al. Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic
T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma. Hepatology
2014;59:567-79.
73. Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol
2015;12:681-700.
74. Chen Y, Huang Y, Reiberger T, Duyverman AM, Huang P, et al. Differential effects of sorafenib on liver versus tumor fibrosis mediated
by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in
mice. Hepatology 2014;59:1435-47.
75. Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda E, et al. A clinical trial of CTLA-4 blockade with tremelimumab in
patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013;59:81-8.
76. El-khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate
040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.
77. Yau T, Park J, Finn R, Cheng A, Mathurin P, et al. CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs
sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol 2019;30:v874-5.
78. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously
treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018;19:940-52.
79. Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, et al; KEYNOTE-240 investigators. Pembrolizumab as second-line therapy
in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol
2020;38:193-202.
80. Yen C, Markman B, Chao Y, Hill A, Kang J, et al. Preliminary results of a phase 1A/1B study of BGB-A317, an anti-PD-1 monoclonal
antibody (mAb), in patients with advanced hepatocellular carcinoma (HCC). Ann Oncol 2017;28:iii54.
81. Qin S, Ren Z, Meng Z, Chen Z, Chai X, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a
multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol 2020;21:571-80.
82. He A, Weiss G, Falchook G, Yee N, Gil-martin M, et al. Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or
metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort (EC) in a phase I study. Ann Oncol 2018;29:x26..
83. Wainberg ZA, Segal NH, Jaeger D, Lee KH, Marshall J, et al. Safety and clinical activity of durvalumab monotherapy in patients with
hepatocellular carcinoma (HCC). J Clin Oncol 2017;35:4071.
84. Floudas CS, Xie C, Brar G, Morelli MP, Fioravanti S, et al. Combined immune checkpoint inhibition (ICI) with tremelimumab and
durvalumab in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinomas (BTC). JCO 2019;37:336.
85. Kelley RK, Abou-alfa GK, Bendell JC, Kim T, Borad MJ, et al. Phase I/II study of durvalumab and tremelimumab in patients with
unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses. JCO 2017;35:4073.
86. Li B, Yan C, Zhu J, Chen X, Fu Q, et al. Anti-PD-1/PD-L1 blockade immunotherapy employed in treating hepatitis B virus infection-
related advanced hepatocellular carcinoma: a literature review. Front Immunol 2020;11:1037.
87. Pishvaian MJ, Lee MS, Ryoo B, Stein S, Lee K, et al. Updated safety and clinical activity results from a phase Ib study of atezolizumab 1
bevacizumab in hepatocellular carcinoma (HCC). Ann Oncol 2018;29.
88. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, et al; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable
hepatocellular carcinoma. N Engl J Med 2020;382:1894-905.
89. Ikeda M, Sung MW, Kudo M, Kobayashi M, Baron AD, et al. A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients
(pts) with unresectable hepatocellular carcinoma (uHCC). JCO 2018;36:4076.